Author + information
- Salem Badr,
- Omar Aly,
- Omid Fatemi,
- Israel Barbash,
- Sa'ar Minha,
- Hironori Kitabata,
- Lakshmana Pendyala,
- Joshua Loh,
- Rebecca Torguson,
- William Suddath,
- Lowell Satler,
- Augusto Pichard and
- Ron Waksman
HIV+ patients who undergo percutaneous coronary interventions (PCI) have been thought to be at high risk of adverse events. Data regarding the safety of PCI in HIV+ patients is sparse, with no data on long–term outcomes post–PCI.
From April 2003 to September 2011, we compared baseline characteristics and 1–year major adverse cardiovascular events (MACE) among 112 consecutive (HIV+) and 112 (HIV–) control patients matched for age, sex, and diabetes who underwent PCI.
Baseline characteristics were generally comparable between the 2 groups except more African American race and chronic renal insufficiency in the HIV+ group than in the HIV– group (62.5 vs. 21.4%, p = <0.001) and (27.7 vs. 9.9%. p = <0.001), respectively. There were no significant differences in other cardiovascular risk factors or in the use of drug–eluting stents. There was no correlation between CD4 count and extent of coronary artery disease. Procedural success rates and occurrence of MACE at 1 year were not significantly different in both groups. (Table) In a multivariable analysis, the only independent correlates of MACE at the end of the follow–up were renal replacement therapy (OR:4.51; p=0.005), acute myocardial infarction (OR: 2.39; p=0.026), and diabetes (OR: 2.18; p=0.05).
HIV+ patients had similar success and 1–year cardiovascular events as HIV– patients. The presence of HIV infection should not be prohibitive to performing PCI in patients who are otherwise appropriate candidates.
Poster Sessions, Expo North
Saturday, March 09, 2013, 3:45 p.m.–4:30 p.m.
Session Title: Complex Patients, Diabetes and Renal Insufficiency
Abstract Category: 43. TCT@ACC–i2: Complex Patients, Diabetes, Renal Insufficiency
Presentation Number: 2106–227
- 2013 American College of Cardiology Foundation